Production of Russian flu vaccines in Nicaragua may start on October 22Society & Culture October 22, 7:44
Mascot of 2018 World Cup should be remembered like Olympic Mishka, Mutko saysSport October 22, 6:31
Nineteen people killed, 3 injured in helicopter crash landing in Russia's YamalSociety & Culture October 22, 5:00
Donetsk’s suburb comes under shelling by Ukrainian troopsWorld October 22, 4:16
Russia to host 2018 FIFA World Cup at highest level — MutkoSport October 22, 2:12
Wolf chosen as mascot of 2018 FIFA World Cup in RussiaSport October 22, 2:00
Warming in Russian-British relations not in sight over short term, says expertRussian Politics & Diplomacy October 22, 1:38
Ceasefire agreements signed with 15 more Syrian settlements — Russian Defense MinistryWorld October 22, 0:39
Russian State Duma speaker confirms readiness to meet PACE presidentRussian Politics & Diplomacy October 22, 0:15
SINGAPORE, July 3, 2013 /PRNewswire/ -- NeuroAiD, a stroke treatment based on Traditional Medicine, increases the odds of achieving a better functional outcome, according to research published online in the journal Stroke.
The CHIMES study is an academic international double-blind placebo-controlled clinical trial which included 1100 patients from several countries who had suffered an ischemic stroke of intermediate severity within 72 hours, treated and monitored for 3 months. Researchers found that patients who were taking NeuroAiD at acute stage had an 11 % increase in the odds of achieving independence in function and being able to perform daily activities at the end of three months. This effect was even greater when NeuroAiD was started beyond 48 hours after stroke onset, with an increase of 39%.
The odds ratio was the highest among recently completed stroke trials of neuroprotective agents. The benefit observed is clinically relevant and might have reached statistical significance with a larger sample size. In addition the study confirmed the excellent safety profile of NeuroAiD. Stroke survivors who were on NeuroAiD had fewer adverse events than those in the control group. Further studies will likely look into the benefits of longer duration of treatment.
Prof Christopher Chen, neurologist at the National University of Singapore and the principal investigator of the CHIMES study, said the results looked very promising and suggested that the effectiveness of such herbal supplements could have a great impact on stroke management. "I think one thing which is very clear is that NeuroAiD is safe in acute stroke. A previous meta-analysis suggested that NeuroAiD is efficacious and safe in the chronic stage of stroke. Now the Chimes study has provided us with much more reliable data about the safety and efficacy of NeuroAiD in acute stroke. I think the CHIMES results are not only a step forward, but also a major achievement."
Each year, 20 million people suffer from the devastating disease. However, there are only a few effective, generally accepted and specific treatments available. Therefore, there is an increasing need for multi-modal therapies to help more patients recover quickly and effectively from stroke. Moleac, a Singapore based bio-pharma company, developed NeuroAiD to meet this need.